eViralHepatitis Review

Take our post-test to claim CME credits. To read a companion newsletterclick here. Hepatitis C has become “curable” for >90% of those infected.But whileuniversalHCV eliminationis medically possible,this goal is compromised bycertain populationswho remainunderscreened, undertreated, and underserved and continue to spreadthe virus. One such population is people who inject drugs(PWID). In this issue,Dr.Brianna Nortonand Dr.Matthew AkiyamafromtheAlbert Einstein College of Medicineanalyze the most important data to explain how substance use impactsadherence and the risk ofHCVreinfection.

Take our post-test to claim CME credits. To read a companion newsletterclick here. The extrahepatic manifestations of chronic HCV can affect many different organ systems. In thiseViralHepatitis Review podcast, Dr. Rajender Reddy from the University of Pennsylvania’s Perelman School of Medicine discusses clinical approaches to identifying and managing the effects of HCV infection beyond the liver.

In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here.

In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss how their analysis of the newer published information can impact clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication. In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment. Take our post-test to claim CME credits. To read a companion newsletter click here.

Among the many extrahepatic complications of hepatitis C infection that contribute to increased morbidity and mortality are CV (cryoglobulinemic vasculitis) and CKD chronic kidney disease).In this issue, Dr. Paul Martin and Dr. Kalyan Ram Bhamidimarri from the Miller School of Medicine at the University of Miami discuss identification and management of these HCV-related comorbidities.To read a companion newsletter click here.